JNJ - FDA finds multiple deficiencies in inspection of troubled Emergent Biosolutions plant

A recently concluded FDA inspection of Emergent BioSolutions (EBS) troubled Baltimore facility has found nine observations of deficiencies.One of them was that the company failed to adequately train employees in manufacturing operations and quality control.Emergent has suspended COVID-19 vaccine production at the site until "the completion of the inspection and remediation."In late March, 15M doses of Johnson & Johnson's (JNJ) COVID-19 vaccine were rendered useless after a manufacturing mix-up at the facility.The inspection also found that equipment in the facility is not of adequate size, drug components were not stored properly to prevent contamination, and the building itself is not maintained in a clean and sanitary condition.Emergent shares are up 0.6% to $65.98 in morning trading.

For further details see:

FDA finds multiple deficiencies in inspection of troubled Emergent Biosolutions plant